Date:
Wed, 05 Aug 2026 12:46:48 EDT
Content:
The U.S. Food and Drug Administration (FDA) has issued a recent update regarding Regeneron Pharmaceuticals, Inc., specifically identifying the company’s manufacturing operations located in East Greenbush, New York. The entry, published in August 2026, references regulatory activity linked to a site inspection or compliance review conducted earlier in the year.
This public notice serves as a standard record of the FDA’s oversight of pharmaceutical manufacturing facilities. The East Greenbush site is a critical component of Regeneron’s production infrastructure, and such updates are part of the agency’s ongoing commitment to ensuring that drug manufacturers maintain high standards of quality and safety.
Industry experts and stakeholders monitor these postings to track the status of facility inspections and the resolution of any regulatory inquiries. Further details regarding the specific nature of the FDA’s observations are typically found within the agency’s formal inspection reports or correspondence archives.
Source: U.S. Food and Drug Administration
Link:
http://www.fda.gov/about-fda/regeneron-pharmaceuticals-inc
Keywords:
FDA, Regeneron Pharmaceuticals, East Greenbush, Pharmaceutical Manufacturing, Compliance Update